Propranolol
Regulatory milestones approvals, filings & regulatory actions · 9 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Hemangiol | — | 2014-04-23 | europa.eu ↗ |
| Label expansions (3) | US (FDA) | INDERAL LA | — | 1984-01-09 – 1987-03-18 | fda.gov ↗ |
| Label expansions (4) | US (FDA) | INDERAL | — | 1979-01-17 – 1986-10-31 | fda.gov ↗ |
| Approved | US (FDA) | INDERAL | — | 1967-11-13 | fda.gov ↗ |
Trials 229 · started per year
Also used as a comparator or background therapy in 144 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 05 trials | ||||||
| Phase 0 | NCT06621004 Comparator | Aug → Dec 2024 overdue | — | Ain Shams University | Enrolling by invitation | No outcome recorded |
| Phase 0 | NCT06262061 Comparator | Mar 2024 → Apr 2025 | traumatic brain injury | London Health Sciences Centre | Unknown | No outcome recorded |
| Phase 0 | NCT04833218 Comparator | Jan 2020 → Jun 2021 | traumatic brain injury | Minia University | Unknown | No outcome recorded |
| Phase 0 | NCT03079921 Comparator | Jan 2017 → Apr 2019 | hypoglycemia, type 1 diabetes mellitus | University of Pennsylvania | Completed | No outcome recorded |
| Phase 0 | NCT02467400 Comparator | Jul 2015 → Oct 2017 | postmenopausal osteoporosis | Mayo Clinic | Completed | No outcome recorded |
| Phase 112 trials | ||||||
| Phase 1 | NCT04713657 Comparator | Dec 2022 → Dec 2030 expected | double outlet right ventricle, tetralogy of fallot | Weill Medical College of Cornell University | Recruiting | No outcome recorded |
| Phase 1 | NCT05189977 Comparator | Sep 2022 → Aug 2023 | post-traumatic stress disorder | Otsuka Pharmaceutical Development & Commercialization, Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT04741698 Comparator | Jul 2021 → Jun 2022 | dystocia | Christiana Care Health Services | Completed | No outcome recorded |
| Phase 1 | NCT03893617 Comparator | Oct 2017 → Jan 2022 | DNA repair disease | Dana Bovbjerg | Terminated | No outcome recorded |
| Phase 1 | NCT03029845 Comparator | Jan 2017 → Apr 2018 | fibromyalgia | University of Utah | Terminated | No outcome recorded |
| Phase 1 | NCT02509559 Comparator | Oct 2013 → Feb 2014 | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1 | NCT01347541 Background | Jan → Nov 2011 | post-traumatic stress disorder | University of Washington | Terminated | No outcome recorded |
| Phase 1 | NCT02012777 Comparator | Jun 2010 → Nov 2012 | sickle cell disease | University of Miami | Terminated | No outcome recorded |
| Phase 1 | NCT00902161 Background | May → Oct 2009 | type 2 diabetes mellitus | Merck Sharp & Dohme LLC | Completed | No outcome recorded |
| Phase 1 | NCT00647816 Comparator | Sep 2005 | — | Mylan Pharmaceuticals Inc | Completed | No outcome recorded |
| Phase 1 | NCT00748059 Background | Dec 1996 → Dec 2020 | autonomic nervous system disorder, disorder of catecholamine synthesis, orthostatic hypotension | Vanderbilt University Medical Center | Completed | No outcome recorded |
| Phase 1 | NCT00889096 Comparator | — | — | University Medicine Greifswald | Completed | No outcome recorded |
| Phase 1/24 trials | ||||||
| Phase 1/2 | NCT06833320 Comparator | Sep 2025 → Sep 2028 | congenital heart disease | June Wu | Suspended | No outcome recorded |
| Phase 1/2 | NCT06836856 Comparator | Jan → Jun 2025 overdue | traumatic brain injury | Mansoura University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03251326 Comparator | Oct 2015 → Jun 2019 | cannabis dependence, post-traumatic stress disorder | New York State Psychiatric Institute | Terminated | No outcome recorded |
| Phase 1/2 | NCT01343329 Comparator | Jul 2011 → Feb 2014 | dysautonomia, traumatic brain injury | Johns Hopkins University | Withdrawn | No outcome recorded |
| Phase 219 trials | ||||||
| Phase 2 | NCT06158230 Comparator | Mar → Nov 2023 | migraine disorder | Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh | Unknown | No outcome recorded |
| Phase 2 | NCT05561751 Background | Feb 2023 → Sep 2025 | plasma cell myeloma | GPCR Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT04186286 Comparator | Feb 2021 → Dec 2025 overdue | postural orthostatic tachycardia syndrome | University of Calgary | Recruiting | No outcome recorded |
| Phase 2 | NCT04533841 Comparator | Feb → Sep 2020 | — | Ahmed mohamed fathy ismail | Completed | No outcome recorded |
| Phase 2 | NCT03838029 Comparator | Nov 2019 → Jan 2026 | malignant pancreatic neoplasm | Assaf-Harofeh Medical Center | Unknown | No outcome recorded |
| Phase 2 | NCT04320589 Comparator | Jun 2019 → Aug 2021 | pheochromocytoma | National Cancer Institute, Egypt | Completed | No outcome recorded |
| Phase 2 | NCT03919461 Comparator | Feb 2019 → Feb 2027 expected | colorectal neoplasm | Assaf-Harofeh Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT03364075 Comparator | Sep 2017 → May 2018 | — | Mark Ware | Terminated | No outcome recorded |
| Phase 2 | NCT03049306 Comparator | Feb 2017 → May 2024 | obstructive sleep apnea syndrome | Johns Hopkins University | Completed | No outcome recorded |
| Phase 2 | NCT02641314 Background | Dec 2016 → Jun 2023 | neuroblastoma | University of Cologne | Completed | No outcome recorded |
| Phase 2 | NCT02437383 Comparator | Aug 2015 → Apr 2018 | temporomandibular joint disorder | University of North Carolina, Chapel Hill | Completed | No outcome recorded |
| Phase 2 | NCT01822587 Comparator | Sep 2013 → Nov 2018 | cocaine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT01072045 Comparator | Jan 2010 → Dec 2014 | hemangioma | University of Sao Paulo | Completed | No outcome recorded |
| Phase 2 | NCT01055171 Comparator | Jan 2010 → Aug 2012 | alcohol dependence, post-traumatic stress disorder | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT01222091 Comparator | Feb 2009 → May 2011 | — | Stanford University | Completed | No outcome recorded |
| Phase 2 | NCT00830362 Comparator | Feb 2009 → Jul 2011 | cocaine dependence | Medical University of South Carolina | Completed | No outcome recorded |
| Phase 2 | NCT00693472 Background | Aug 2007 → Dec 2008 | drug-induced akathisia, movement disorder | Merck Sharp & Dohme LLC | Terminated | No outcome recorded |
| Phase 2 | NCT00651235 Comparator | Feb 2007 → Feb 2011 | Marfan syndrome | National Taiwan University Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT00527319 Comparator | Jan 2007 → Aug 2008 | hypoproteinemia, hypercatabolic | Vicus Therapeutics | Completed | No outcome recorded |
| Phase 2/311 trials | ||||||
| Phase 2/3 | NCT03720067 Comparator | Jan 2019 → Dec 2020 | cirrhosis of liver, esophageal varices with bleeding, portal hypertension | Federal University of Rio de Janeiro | Unknown | No outcome recorded |
| Phase 2/3 | NCT03609307 Comparator | Sep → Oct 2018 | wet macular degeneration | Shahid Beheshti University of Medical Sciences | Unknown | No outcome recorded |
| Phase 2/3 | NCT02962947 Comparator | Jun 2017 → Jun 2019 | melanoma | Azienda Sanitaria di Firenze | Unknown | No outcome recorded |
| Phase 2/3 | NCT04140591 Comparator | Dec 2016 → Oct 2019 | cirrhosis of liver, peptic ulcer disease | Taipei Veterans General Hospital, Taiwan | Terminated | No outcome recorded |
| Phase 2/3 | NCT02452255 Comparator | Nov 2015 → Dec 2018 | — | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT01957449 Comparator | Dec 2013 → Dec 2018 | — | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT01902810 Comparator | Jul 2013 → Jun 2019 | — | The University of Texas Medical Branch, Galveston | Terminated | No outcome recorded |
| Phase 2/3 | NCT01897051 Background | Jul 2013 → Feb 2017 | cirrhosis of liver, portal hypertension | Yonsei University | Unknown | No outcome recorded |
| Phase 2/3 | NCT01061190 Comparator | Jan 2010 → Oct 2011 | stroke disorder | Wilhelm Haverkamp | Completed | No outcome recorded |
| Phase 2/3 | NCT01007994 Comparator | Nov 2009 → Jan 2020 | secondary hypertension | Northwell Health | Completed | No outcome recorded |
| Phase 2/3 | NCT00884663 Comparator | Apr 2009 → Mar 2012 | migraine with aura, migraine without aura | Norwegian University of Science and Technology | Completed | No outcome recorded |
| Phase 318 trials | ||||||
| Phase 3 | NCT07147972 Comparator | Aug 2025 → Feb 2026 overdue | migraine disorder | Fayoum University | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05427474 Comparator | Dec 2022 → Sep 2023 | traumatic brain injury | Zagazig University | Unknown | No outcome recorded |
| Phase 3 | NCT04299438 Comparator | Jul 2020 → Jun 2022 | pregnancy disorder | Lisa Levine | Terminated | No outcome recorded |
| Phase 3 | NCT03303053 Comparator | May 2017 → Mar 2018 | Graves disease | Clinical Research Centre, Malaysia | Unknown | No outcome recorded |
| Phase 3 | NCT03237637 Comparator | Mar 2017 → Dec 2018 | hemangioma | Post Graduate Institute of Medical Education and Research, Chandigarh | Unknown | No outcome recorded |
| Phase 3 | NCT02702674 Comparator | Dec 2015 → Dec 2016 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT02505971 Comparator | Sep 2015 → Apr 2020 | hemangioma | The Hospital for Sick Children | Completed | No outcome recorded |
| Phase 3 | NCT02649335 Comparator | Jul 2015 → Dec 2016 | — | Post Graduate Institute of Medical Education and Research, Chandigarh | Completed | No outcome recorded |
| Phase 3 | NCT02853526 Comparator | Jul 2015 → Dec 2017 | cirrhosis of liver, esophageal varices with bleeding, portal vein thrombosis, portal vein, cavernous transformation of | Zaibo Jiang | Unknown | No outcome recorded |
| Phase 3 | NCT02132767 Comparator | May 2014 → Sep 2015 | atrial fibrillation | Icahn School of Medicine at Mount Sinai | Completed | No outcome recorded |
| Phase 3 | NCT02342275 Comparator | Oct 2013 → Sep 2018 | hemangioma | West China Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01239173 Comparator | Sep 2010 → Nov 2011 | post-traumatic stress disorder | Assistance Publique - Hôpitaux de Paris | Terminated | No outcome recorded |
| Phase 3 | NCT00888797 Comparator | Jan 2010 → Jan 2017 | colorectal neoplasm | Sheba Medical Center | Unknown | No outcome recorded |
| Phase 3 | NCT00772031 Comparator | Oct 2008 → Sep 2010 | migraine disorder | Anne Lindblad | Completed | No outcome recorded |
| Phase 3 | NCT00916721 Comparator | Apr 2008 → Jul 2010 | — | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01000779 Comparator | Jan 2005 → Oct 2009 | portal hypertension, noncirrhotic | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| Phase 3 | NCT00493480 Comparator | Sep 2003 → Aug 2009 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Completed | No outcome recorded |
| Phase 3 | NCT01134692 Background | — | cirrhosis of liver, esophageal varices | Govind Ballabh Pant Hospital | Unknown | No outcome recorded |
| Phase 431 trials | ||||||
| Phase 4 | NCT07655700 Comparator | Jul 2026 → Mar 2027 expected | — | Chittagong Medical College | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07655440 Comparator | Jul 2026 → Jul 2031 expected | migraine disorder, tinnitus, vestibular disorder | Stanford University | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT07352228 Comparator | Jan → Sep 2026 expected | portal hypertension | Xijing Hospital | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT06972056 Comparator | Jul 2025 → Mar 2029 expected | migraine disorder | Mayo Clinic | Recruiting | No outcome recorded |
| Phase 4 | NCT06982183 Comparator | May 2025 → Sep 2026 expected | acute stress disorder | Walter Reed Army Institute of Research (WRAIR) | Recruiting | No outcome recorded |
| Phase 4 | NCT06499116 Comparator | Oct 2024 → Dec 2026 expected | migraine disorder | Jordi Gol Institute for Primary Care Research | Not yet recruiting | No outcome recorded |
| Phase 4 | NCT06485726 Comparator | Jan 2023 → Jul 2024 overdue | migraine disorder | Kafrelsheikh University | Recruiting | No outcome recorded |
| Phase 4 | NCT05106179 Comparator | Dec 2021 → Dec 2022 | hemangioma, poisoning, spinal cord neoplasm | Center for Vascular Pathology, Moscow | Unknown | No outcome recorded |
| Phase 4 | NCT05195996 Comparator | Oct 2021 → Mar 2022 | traumatic brain injury | Menoufia University | Completed | No outcome recorded |
| Phase 4 | NCT04757584 Comparator | Apr 2021 → Apr 2023 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04767061 Comparator | Apr 2021 → Apr 2022 | diastolic heart failure | Weill Medical College of Cornell University | Completed | No outcome recorded |
| Phase 4 | NCT04406870 Background | Jul 2020 → Jun 2024 | hemangioendothelioma | Shanghai Children's Medical Center | Unknown | No outcome recorded |
| Phase 4 | NCT04288700 Comparator | Oct 2019 → Dec 2020 | hemangioma | Ain Shams University | Unknown | No outcome recorded |
| Phase 4 | NCT07405229 Comparator | May 2018 → Dec 2032 expected | cardiac arrest, ventricular fibrillation | Bo Gregers Winkel | Recruiting | No outcome recorded |
| Phase 4 | NCT03401515 Comparator | Oct 2016 → Jun 2017 | traumatic brain injury | Ain Shams University | Completed | No outcome recorded |
| Phase 4 | NCT02934763 Comparator | Oct 2016 → Apr 2017 | — | Pontificia Universidad Catolica de Chile | Unknown | No outcome recorded |
| Phase 4 | NCT02670161 Comparator | May 2016 → Dec 2026 expected | Parkinson disease, brain neoplasm, cognitive impairment with or without cerebellar ataxia, epilepsy +6 | Endeavor Health | Enrolling by invitation | No outcome recorded |
| Phase 4 | NCT04074473 Comparator | Apr → Nov 2015 | acute kidney injury, cirrhosis of liver, esophageal varices | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT02385422 Comparator | Mar 2015 → Jun 2017 | cirrhosis of liver, esophageal varices, hemorrhagic disease | Shanghai Zhongshan Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT02171988 Comparator | Mar 2014 → Feb 2016 | postural orthostatic tachycardia syndrome | Seoul National University Hospital | Completed | No outcome recorded |
| Phase 4 | NCT02350985 Comparator | Jan → Sep 2014 | migraine disorder | Haseki Training and Research Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01631682 Comparator | Nov 2010 → Jan 2015 | post-traumatic stress disorder | Massachusetts General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01298271 Comparator | Apr 2010 → Dec 2025 | cirrhosis of liver | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01298284 Comparator | Oct 2009 → Jun 2010 | cirrhosis of liver, hepatocellular carcinoma | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01970748 Comparator | Aug 2009 → Dec 2023 | esophageal varices with bleeding, hepatocellular carcinoma | Taipei Veterans General Hospital, Taiwan | Unknown | No outcome recorded |
| Phase 4 | NCT01893541 Comparator | Jun 2008 → Jun 2011 | cirrhosis of liver, esophageal varices | Federal University of São Paulo | Completed | No outcome recorded |
| Phase 4 | NCT01476930 Comparator | Jun 2008 → Sep 2009 | migraine disorder | Birjand University of Medical Sciences | Completed | No outcome recorded |
| Phase 4 | NCT00965900 Comparator | Sep 2006 → May 2019 | cirrhosis of liver, esophageal varices with bleeding | Korea University | Unknown | No outcome recorded |
| Phase 4 | NCT01458600 Background | Sep 2006 → Feb 2016 | Graves disease | Mikael Lantz | Completed | No outcome recorded |
| Phase 4 | NCT00332904 Comparator | Aug 2006 → Jul 2008 | cirrhosis of liver, portal hypertension | Hvidovre University Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT00910689 Comparator | Jul 2001 → Nov 2005 | migraine disorder | Ohio University | Completed | No outcome recorded |
| Phase not applicable44 trials | ||||||
| — | NCT07168395 Comparator | Oct 2026 → Nov 2027 expected | — | University of California, Los Angeles | Not yet recruiting | No outcome recorded |
| — | NCT07587671 Background | Aug 2026 → Mar 2029 expected | cirrhosis of liver, esophageal varices with bleeding, hepatic encephalopathy, portal hypertension | West China Hospital | Not yet recruiting | No outcome recorded |
| — | NCT07652203 Comparator | Jun 2026 → Jul 2027 expected | cirrhosis of liver | General Hospital of Shenyang Military Region | Not yet recruiting | No outcome recorded |
| — | NCT07568574 Background | Mar 2026 → May 2028 expected | — | Enhanced Emirates Limited | Enrolling by invitation | No outcome recorded |
| — | NCT07067853 Comparator | Sep → Dec 2025 | migraine disorder | Indonesia University | Completed | No outcome recorded |
| — | NCT07111221 Background | Jun 2025 → Oct 2029 expected | cirrhosis of liver, portal hypertension | Medical University of Warsaw | Recruiting | No outcome recorded |
| — | NCT06422494 Comparator | Jan → Sep 2025 overdue | type 1 diabetes mellitus | Radboud University Medical Center | Active not recruiting | No outcome recorded |
| — | NCT07560332 Comparator | Jan 2025 → Jan 2026 | hemangioma | Cairo University | Completed | No outcome recorded |
| — | NCT07113015 Comparator | Jul → Dec 2024 | Parkinson disease, movement disorder | Multan Medical And Dental College | Completed | No outcome recorded |
| — | NCT07104526 Comparator | Jan 2024 → Jan 2025 | hemangioma | Wuhan Integrated Traditional Chinese and Western Medicine Hospital | Completed | No outcome recorded |
| — | NCT05690737 Comparator | Sep 2023 → Dec 2025 overdue | migraine disorder | The Hong Kong Polytechnic University | Recruiting | No outcome recorded |
| — | NCT06670690 Comparator | Sep 2023 | — | Menoufia University | Completed | No outcome recorded |
| — | NCT05859009 Comparator | Jul 2023 → Jul 2025 | varicose disease | Unity Health Toronto | Withdrawn | No outcome recorded |
| — | NCT05651789 Comparator | Jan 2023 → Dec 2024 | cirrhosis of liver, portal hypertension, varicose disease | West China Hospital | Unknown | No outcome recorded |
| — | NCT06014606 Comparator | Mar 2021 → Apr 2023 | — | Maastricht University | Completed | No outcome recorded |
| — | NCT05251610 Comparator | Nov 2020 → Apr 2021 | — | Darlington-Peter Chibuzor Ugoji | Completed | No outcome recorded |
| — | NCT04208594 Comparator | Dec 2019 → May 2020 | — | Alexandria University | Unknown | No outcome recorded |
| — | NCT04075760 Comparator | Aug 2019 → Aug 2020 | cirrhosis of liver | Instituto Ecuatoriano de Enfermedades Digestivas | Unknown | No outcome recorded |
| — | NCT03783065 Background | Jan → Oct 2019 | esophageal varices, portal hypertension | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| — | NCT03569046 Comparator | Jul → Dec 2018 | — | Abd-Elazeem Abd-Elhameed Elbakry | Completed | No outcome recorded |
| — | NCT03832712 Comparator | Jun 2018 → Jan 2026 overdue | essential tremor | Karolinska Institutet | Recruiting | No outcome recorded |
| — | NCT03461874 Background | Mar 2018 → Jul 2020 | migraine without aura | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | Completed | No outcome recorded |
| — | NCT03422354 Comparator | Feb → May 2018 | — | Cairo University | Completed | No outcome recorded |
| — | NCT03434444 Comparator | Sep 2017 → Aug 2022 | — | Samuel Lunenfeld Research Institute, Mount Sinai Hospital | Completed | No outcome recorded |
| — | NCT02485184 Comparator | Jul 2017 → Dec 2024 | cirrhosis of liver, portal vein thrombosis | Air Force Military Medical University, China | Unknown | No outcome recorded |
| — | NCT03094234 Comparator | Apr 2017 → Mar 2022 | portal hypertension | West China Hospital | Unknown | No outcome recorded |
| — | NCT03533699 Comparator | Oct 2016 → Jan 2019 | — | Ain Shams Maternity Hospital | Unknown | No outcome recorded |
| — | NCT02808611 Comparator | Jul 2016 → Jan 2017 | — | Kristian Kjær Petersen | Completed | No outcome recorded |
| — | NCT02477384 Comparator | Jun 2015 → Nov 2018 | portal hypertension | West China Hospital | Completed | No outcome recorded |
| — | NCT02179775 Comparator | Jul → Sep 2014 | migraine disorder, stomach disorder | Shiraz University of Medical Sciences | Unknown | No outcome recorded |
| — | NCT01117454 Background | Dec 2011 → Dec 2015 | catecholaminergic polymorphic ventricular tachycardia | Vanderbilt University Medical Center | Completed | No outcome recorded |
| — | NCT01370161 Comparator | Jul 2011 → Sep 2018 | cirrhosis of liver, esophageal varices with bleeding | Air Force Military Medical University, China | Completed | No outcome recorded |
| — | NCT01069159 Comparator | Feb 2010 → Sep 2011 | post-traumatic stress disorder | Mela, Mansfield, M.D. | Unknown | No outcome recorded |
| — | NCT01094574 Comparator | Jan → Jun 2010 | — | Martin Angst | Completed | No outcome recorded |
| — | NCT00911508 Comparator | Nov 2009 → Dec 2017 | atrial fibrillation | Mayo Clinic | Completed | No outcome recorded |
| — | NCT00588965 Comparator | Aug 2007 → Dec 2008 | long QT syndrome | MetroHealth Medical Center | Completed | No outcome recorded |
| — | NCT00777218 Comparator | Aug 2007 → Dec 2010 | migraine disorder | University of South Alabama | Withdrawn | No outcome recorded |
| — | NCT00888784 Comparator | Aug 2006 → Jan 2009 | cirrhosis of liver | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| — | NCT00745043 Comparator | May 2005 → Aug 2007 | chronic obstructive pulmonary disease | Waikato Hospital | Completed | No outcome recorded |
| — | NCT00772057 Comparator | Oct 2004 → Oct 2008 | cirrhosis of liver | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| — | NCT00597389 Comparator | Feb 2004 → Nov 2005 | post-traumatic stress disorder | Kent State University | Completed | No outcome recorded |
| — | NCT00684489 Comparator | Sep 2003 → Mar 2005 | essential hypertension | Medical University of South Carolina | Completed | No outcome recorded |
| — | NCT00766805 Comparator | Oct 2002 → Dec 2006 | portal hypertension | Govind Ballabh Pant Hospital | Completed | No outcome recorded |
| — | NCT00608725 Background | Dec 1996 → Dec 2029 expected | cardiac rhythm disease, postural orthostatic tachycardia syndrome | Satish R. Raj | Active not recruiting | No outcome recorded |
Evidence & citations 26 cited values
Every value below carries the sentence it was read from. 377 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | propranolol | “The study investigates the tolerance and the efficacy of a new combination of five drugs consisting of propranolol (antiangiogenetic, anti-neuroblastic), Celecoxib (modulating...” NCT02641314 ↗353“Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine, sertraline,...” NCT01347541 ↗ “Participants assigned to receive the combination therapy may receive one or more of the following medications based on their individual needs: fluoxetine; sertraline;...” NCT00270959 ↗ “The betablocker given to the patient will be prioritized: 1) A non-selective betablocker: Propranolol Retard 80 mg daily or Nadolol 40 mg daily OR 2) A selective betablocker:...” NCT07405229 ↗ “There is evidence that the non-selective beta-blocker (NSBB) propranolol reduces intestinal permeability and decreases bacterial translocation in cirrhotic patients,...” NCT02484573 ↗ “Propranolol (10 mg orally or via nasogastric tube, three times daily) or Esmolol (1 g in 40 mL saline, IV infusion at no less than 2 mL/h; use for no more than 48 hours. Beyond...” NCT06863558 ↗ “Other names: acebutolol, atenolol, betaxolol, bisoprolol, carvedilol, labetalol, metoprolol, metoprolol succinate, metoprolol tartrate, nadolol, nebivolol, propranolol,...” NCT05585125 ↗ “Other Names: * acebutolol * atenolol * betaxolol * bisoprolol * carvedilol * labetalol * metoprolol succinate * metoprolol tartrate * nadolol * nebivolol * penbutolol *...” NCT05019027 ↗ “The aim of the study was to compare the clinical efficacy of acebutolol (10mg/Kg/jour) and propranolol (3mg/Kg/j) on the proliferative phase of infantile hemangioma in infants.” NCT01743885 ↗ “Significant reduction of portal pressure is observed in up to 50% of patients treated with propranolol and up to 75% with carvedilol.” NCT07111221 ↗ “Participants will take 1.5 mg/kg/day propranolol, twice daily for 3 weeks until surgical resection of the breast tumor is performed” NCT02596867 ↗ “The present study will employ a psychopharmacological approach to experimentally block SNS activity using the drug propranolol.” NCT02972554 ↗ “The following will be used in the study for VT-122: propranolol 22 mg immediate-release capsules and etodolac 340 mg capsules.” NCT01857817 ↗ “Beta-blocker medication consists of 80 mg/day of propranolol (Inderal LA 80), aspirin will be given in a dose of 100 mg/day.” NCT00174902 ↗ “Beta-blockers, specifically metoprolol and propranolol, are one of the first-line treatments for migraine prophylaxis.” NCT05690737 ↗ “Standard therapy with beta-blocker (nadolol, atenolol, metoprolol, or propranolol) continues throughout the trial.” NCT01117454 ↗ “hypotensives for deliberate hypotension by nitroglycerine 0.5-10 μg /kg/min and increments of 0.2 mg propranolol” NCT03569046 ↗ “then a non-selective beta-blocker (propranolol) will be started with an initial dose of 40 mg” NCT01370161 ↗ “Propranolol may be used if carvedilol is not tolerated or is clinically inappropriate.” NCT07587671 ↗ “hypotensive drugs ( propranolol and nitroglycerineand the total dose will be recorded.” NCT03422354 ↗ “they are goning to take propranolol (dose of propranolol 80 mg per day) for 4 weeks” NCT02923336 ↗ “addition to propranolol (Inderal®) 10 mg once daily titrated as patient's response.” NCT04704947 ↗ “o Beta-blocker (propranolol) will be started at dose of 20 mg twice daily.” NCT04075760 ↗ “Propranolol (10 mg orally or via nasogastric tube, three times daily)” NCT06863571 ↗ “Group A: Included those who had to be managed with oral propranolol.” NCT05327309 ↗ “under the influence of the ß-adrenergic blocking drug propranolol” NCT03652922 ↗ “Salbutamol 8mg M/R Tablet, Propranolol 40 mg administered orally” NCT03524066 ↗ “anticholinergic agents or propranolol as a rescue medication” NCT00693472 ↗ “Atenolol 50-100mg, Propranolol 40-80mg, Acebutolol 200-300mg” NCT00911508 ↗ “nortriptyline ,propranolol ,ergotamine , sumatriptan tablets” NCT01476930 ↗ “bisoprolol, metoprolol, nadolol, propranolol, timolol” NCT00684489 ↗ “These may include propranolol, nadolol, and timolol.” NCT07168395 ↗ “migraine (amitriptyline, propranolol, topiramate)” NCT02670161 ↗ “Propranolol 0.2 mg/kg IV in divided doses” NCT00608725 ↗ “Propranolol (Inderal) :10-360 mg/day” NCT04320589 ↗ “Daily propranolol 80mg capsules” NCT00745043 ↗ “Propranolol 40-80mg” NCT00578617 ↗ “Drug: Propranolol” NCT01950520 ↗ “propranolol” NCT02485184 ↗ “propranolol” NCT04757584 ↗ “propranolol” NCT04767061 ↗ |
| Known as | AVLOCARDYL | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01239173 ↗ |
| Known as | Beta-blocker | “Beta-blocker and/or Calcium channel blockers and/or Digoxin - Dose, frequency and duration determined by medical professional as medically needed” NCT02132767 ↗ |
| Known as | Deralin | “Propranolol (Deralin) - patients will receive a low dose of 40 mg/day (4X10mg) starting two days before surgery” NCT00502684 ↗ |
| Known as | HEMANGIOL | “administration of a propranolol (HEMANGIOL®) and oral metronomic vinorelbine (NAVELBINE®) combination” NCT02897986 ↗ |
| Known as | Inderal | “will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK)” NCT04208594 ↗6“Propranolol Inderal (registered trademark) is a Food and Drug Administration-approved drug that belongs to a class of drugs called beta-blockers.” NCT00060866 ↗ “the addition of a beta-blocker such as Propranolol (Inderal) is tolerable when given with chemotherapy” NCT01308944 ↗ “Propranolol is available in generic form as the Wyeth product under the trade name Inderal.” NCT01127568 ↗ “Propranolol (Inderal) :10-360 mg/day” NCT04320589 ↗ |
| Known as | Inderal LA | “Single-Dose Fed Bioequivalence Study of Propranolol Hydrochloride Extended-Release Capsules (160 mg; Mylan) and Inderal® LA Capsules (160 mg; Wyeth) in Healthy Volunteers” NCT00647608 ↗2“On the CPAP withdrawal nights, Propranolol LA (Inderal ® LA) 80 mg will be administered orally before sleep, at 6:30 PM, after dinner.” NCT03049306 ↗ “Inderal® LA Capsules 160 mg” NCT00647816 ↗ |
| Known as | Inderal (Registered Trademark) | “Propranolol (Inderal® (Registered Trademark)) is a Food and Drug Administration-approved drug that belongs to a class of drugs called beta-blockers.” NCT00093860 ↗ |
| Known as | Inderal LA 80 | “Beta-blocker medication consists of 80 mg/day of propranolol (Inderal LA 80), aspirin will be given in a dose of 100 mg/day.” NCT00174902 ↗ |
| Known as | Inderol | “Drug: Inderol (propranolol)” NCT00597389 ↗ |
| Known as | PPL | “This randomised trial aimed to address whether endoscopic variceal ligation (EVL) or propranolol (PPL) is more effective at preventing initial oesophageal variceal bleeding...” PMID 38123994 ↗ Mar 20241“We aimed to evaluate the safety and efficacy of propranolol (PPL) compared to endoscopic variceal ligation (EVL) for V.H. primary prevention in patients with ascites.” PMID 35672572 ↗ Jun 2022 |
| Known as | PPNL | “The β-adrenergic blocker propranolol (PPNL) possesses such amnestic properties.” NCT05853627 ↗ |
| Known as | prop | “In addition, in cancer cell cultures, catecholamines (norepinephrine and epinephrine) induced an increase of VEGF expression in a tissue culture of nasopharyngeal carcinoma, an...” NCT01238471 ↗1“with propranolol (PROP) as an active control.” PMID 15316798 ↗ Aug 2004 |
| Known as | Propanolol | “Pharmacological prophylaxis will be prescribed based on patients' profile (e.g. previous failures or contraindications), and limited to Topiramate, Propanolol, Amytriptiline or...” NCT03461874 ↗8“Tablet Carbimazole 30 mg daily, Tablet propanolol 40 mg twice daily for 4 weeks” NCT03303053 ↗ “Unselective β-blockers such as Propanolol” NCT03832712 ↗ |
| Known as | Propanolol-CT | “one capsule Propanolol-CT 80 mg Filmtabletten (propranololhydrochloride, film-coated tablet encapsulated, 80 mg, single dose)” NCT02509559 ↗ |
| Known as | Propranolol (slow-Release) | “Name: Propranolol (slow-Release) and Etodolac.” NCT06839144 ↗ |
| Known as | Propranolol Hcl | “Drug: Propranolol Hcl 40mg Tab” NCT04421209 ↗ |
| Known as | Propranolol Hydrochloride | “will receive oral propranolol (INDERAL® -propranolol hydrochloride Ph. Eur. 10mg manufactured by AstraZeneca Egypt under license of AstraZeneca UK)” NCT04208594 ↗24“Treatment initiated with 1 capsule (60 mg long acting propranolol hydrochloride) and increased to 3 capsules (180 mg) at week 12 as tolerated.” NCT00910689 ↗ “drug: 'Propranolol hydrochloride' 338 patients will be enrolled in the "Propranolol" Group and treated with propranolol.” NCT01988831 ↗ “Propranolol hydrochloride is a nonselective beta-adrenergic antagonist that has a known activity in the myometrium.” PMID 33421647 ↗ Jan 2021 “Patients receive propranolol hydrochloride orally (PO) 2 hours prior to standard of care prostatectomy.” NCT03152786 ↗ “Propranolol hydrochloride capsules 160 mg once daily, slow release formulation” NCT00884663 ↗ “Propranolol Hydrochloride Extended-Release Capsules 160 mg” NCT00647816 ↗ “Inderal (propranolol hydrochloride)” NCT01319214 ↗ “Propranolol Hydrochloride 1 MG/ML” NCT06422494 ↗ “Drug: Propranolol Hydrochloride” NCT06787066 ↗ “Drug: Propranolol Hydrochloride” NCT04493489 ↗ “Drug: Propranolol Hydrochloride” NCT03254186 ↗ “Drug: Propranolol Hydrochloride” NCT06445166 ↗ “Drug: Propranolol Hydrochloride” NCT04299438 ↗ “Drug: Propranolol Hydrochloride” NCT05525416 ↗ “Drug: Propranolol Hydrochloride” NCT01555554 ↗ “Drug: Propranolol Hydrochloride” NCT05085782 ↗ “Drug: Propranolol Hydrochloride” NCT05997732 ↗ “Propranolol hydrochloride” NCT05979818 ↗ |
| Known as | Propranolol hydrochloride (USP/EP) Oral Solution | “Propranolol hydrochloride (USP/EP) Oral Solution” NCT01074437 ↗ |
| Known as | propranolol hydrochloride-LA | “If subject does not tolerate at least 2 capsules (120 mg) of propranolol hydrochloride-LA, and in treating neurologist's judgment are unimproved, subject switched to second...” NCT00910689 ↗ |
| Known as | Propranolol LA | “Long-acting propranolol (Propranolol LA) 60 mg to be administered orally daily for Days 1 (before exercise induced muscle injury) and Days 2-4 following exercise induced muscle injury.” NCT02620579 ↗ |
| Known as | V0400 GL 01A | “Pierre Fabre Dermatologie has developed a new formulation of propranolol (V0400 GL 01A) which is a topical gel adapted to paediatric use.” NCT01512173 ↗ |
| Known as | VT-122 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00527319 ↗ |
| Action | Inhibit | “We propose to administer propranolol, a beta-adrenergic receptor blocking medication that is frequently prescribed for the treatment of hypertension, to patients with SAD in the winter.” NCT00016666 ↗ |
| Modality | Small molecule | “beta-blocker” NCT01908972 ↗ |
| Route | Oral | “treatment with oral propranolol” NCT00060866 ↗ |